Aprea Therapeutics Files Routine 8-K on Jan 4, 2024

Ticker: APRE · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1781983

Aprea Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAprea Therapeutics, Inc. (APRE)
Form Type8-K
Filed DateJan 4, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: compliance, regulatory-filing, 8-K

TL;DR

**APRE filed a routine 8-K, no major news.**

AI Summary

Aprea Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates standard, routine reporting by the company, confirming its registration on The Nasdaq Stock Market LLC under the trading symbol APRE. For investors, this filing primarily serves as a confirmation of ongoing compliance and operational status, rather than signaling any new material financial or strategic developments.

Why It Matters

This filing is a standard compliance update, indicating Aprea Therapeutics is meeting its regulatory obligations but doesn't reveal new financial or operational news.

Risk Assessment

Risk Level: low — This 8-K filing is a standard, non-eventful report, indicating no immediate new risks or opportunities.

Analyst Insight

A smart investor would note this as a routine compliance filing and not indicative of any new material information that would warrant immediate action. It's a 'no news is good news' scenario, confirming ongoing regulatory adherence.

Key Numbers

  • 001-39069 — Commission File Number (identifies Aprea Therapeutics' registration with the SEC)
  • 20240104 — Filing Date (the date the 8-K was filed and the earliest event reported)
  • $0.001 — par value per share (the stated par value of Aprea Therapeutics' common stock)

Key Players & Entities

  • Aprea Therapeutics, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market LLC (company) — the exchange where Aprea Therapeutics' common stock is registered
  • APRE (company) — the trading symbol for Aprea Therapeutics' common stock
  • January 4, 2024 (date) — the date of the report and earliest event reported
  • 001-39069 (dollar_amount) — the Commission File Number for Aprea Therapeutics

FAQ

What is the purpose of this 8-K filing by Aprea Therapeutics, Inc.?

This 8-K filing by Aprea Therapeutics, Inc. on January 4, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting 'Other Events' and 'Financial Statements and Exhibits.' It appears to be a routine compliance filing.

On what stock exchange is Aprea Therapeutics, Inc. common stock registered?

Aprea Therapeutics, Inc.'s common stock, with a par value of $0.001 per share, is registered on The Nasdaq Stock Market LLC under the trading symbol APRE.

What is the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 4, 2024, which is also the date of the report.

What is Aprea Therapeutics, Inc.'s business address and phone number?

Aprea Therapeutics, Inc.'s business address is 3805 Old Easton Road, Doylestown, PA 18902, and its telephone number is (617) 463-9385.

Is Aprea Therapeutics, Inc. considered an emerging growth company according to this filing?

The filing includes a checkbox to indicate whether the registrant is an emerging growth company, but the box is not checked, implying that Aprea Therapeutics, Inc. does not identify itself as an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act.

Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-04 16:16:01

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 4, 2024, Aprea Therapeutics, Inc. issued a press release announcing a corporate update and development plans for 2024 and updated its corporate presentation slide deck. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated January 4, 2024. 99.2 Corporate Presentation (January 2024) 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: January 4, 2024 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.